US Bancorp’s Beta Bionics BBNX Stock Holding History

US Bancorp’s Portfolio BBNX Stock Details BBNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.21K	Buy	221 +192	+662%	+$2.84K	﹤0.01%	3779
2025 Q4	$884	Buy	+29	New	+$774	﹤0.01%	3872

Other funds holding BBNX

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

US Bancorp's BBNX Position: Q1 2026 in Review

US Bancorp increased its Beta Bionics (BBNX) stake by 662% in Q1 2026, buying an estimated $2.84K and bringing the position to 221 shares worth $2.21K. The position accounts for ﹤0.01% of the portfolio, ranked #3779.

US Bancorp first reported a position in BBNX in Q4 2025 and has held it in 2 quarters since. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

US Bancorp held 221 shares of Beta Bionics worth $2.21K as of Q1 2026.
US Bancorp bought 192 Beta Bionics shares in Q1 2026, an estimated $2.84K.
Beta Bionics made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3779 holding.
US Bancorp first reported a position in Beta Bionics in Q4 2025 and has held it in 2 quarters since.
130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.